Bristol-Myers Squibb (BMY)

The sleeper story is Eliquis transforming from mature cash cow to growth driver through aggressive pricing that Wall Street hasn't fully appreciated. While everyone focuses on pipeline delays like ADEPT-2's Q4 miss, BMY is making a calculated bet that a 40% price cut can reignite 10-15% growth in their largest brand by eliminating accumulated rebate penalties. The binding constraint is pipeline execution timing, with six critical readouts crammed into H2 2026 creating binary risk concentration. Management's most revealing comment: 'The 40% WAC reduction eliminates inflationary penalties of statutory rebates that have been accumulating over many years' - this isn't just IRA compliance, it's strategic repositioning. My view changes if CoBinfy TRx data shows actual plateau rather than just reduced disclosure, or if any of the six H2 readouts get pushed into 2027.